SIHUAN PHARM (00460) saw its shares climb more than 4% on Wednesday, with the stock surging over 17% at one point after the company issued a profit alert midday. As of the latest trading, the stock was up 4.55% at HK$0.92, with a turnover of HK$110 million.

On July 27, SIHUAN PHARM announced that the group expects to record revenue of no less than RMB 1.14 billion for the six months ended June 30, 2026, roughly flat compared to the same period last year. The group also anticipates net profit of no less than RMB 210 million for the period, representing a year-on-year increase of no less than 217.2%.

During the reporting period, the group's medical aesthetics segment continued to benefit from the stable growth of its core product, Letybo® (botulinum toxin), as well as the ongoing volume expansion of regenerative aesthetic products (including dermal fillers for collagen stimulation and polycaprolactone-based fillers) and functional aesthetic products. This drove sustained revenue growth in the related business. The medical aesthetics business generated revenue of no less than RMB 680 million for the period, up no less than 16.1% year-on-year. The segment's profit contribution was no less than RMB 320 million, continuing to serve as a significant source of earnings for the group.

Additionally, the group's innovative drug business has seen steady progress in its commercialization. The commercialization and internationalization of several approved products are progressing well, leading to a substantial increase in combined revenue and a significant reduction in losses.